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Abstract
Human hepatocytes are the gold standard for toxicological studies but they have several drawbacks, like scarce availability,
high inter-individual variability, a short lifetime, which limits their applicability. The aim of our investigations was to
determine, whether HepaRG cells could replace human hepatocytes in uptake experiments for toxicity studies. HepaRG is a
hepatoma cell line with most hepatic functions, including a considerable expression of uptake transporters in contrast to
other hepatic immortalized cell lines. We compared the effect of cholestatic drugs (bosentan, cyclosporinA, troglitazone,)
and bromosulfophthalein on the uptake of taurocholate and estrone-3-sulfate in human and rat hepatocytes and HepaRG
cells. The substrate uptake was significantly slower in HepaRG cells than in human hepatocytes, still, in the presence of
drugs we observed a concentration dependent decrease in uptake. In all cell types, the culture time had a significant impact
not only on the uptake process but on the inhibitory effect of drugs too. The most significant drug effect was measured at
4 h after seeding. Our report is among the first concerning interactions of the uptake transporters in the HepaRG, at the
functional level. Results of the present study clearly show that concerning the inhibition of taurocholate uptake by
cholestatic drugs, HepaRG cells are closer to human hepatocytes than rat hepatocytes. In conclusion, we demonstrated that
HepaRG cells may provide a suitable tool for hepatic uptake studies.
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Introduction
Drug-induced liver injury is one of the major reasons for the
withdrawal of an approved drug from the market [1], [2]. These
drugs show only a minor or no signs of hepatotoxicity in the
animal species tested, indicating, that there is often poor
correlation of toxicity from one species to another. Primary
cultures of hepatocytes are the most common experimental system
for studying in vitro drug metabolism and drug-transporter
interactions [3], [4]. However, the use of human hepatocytes for
toxicological studies has several drawbacks, such as their
unpredictable and scarce availability, inter-individual variability,
limited life span and phenotypic alterations [5]. These concerns
have led to a call for alternative systems to screening and
identifying potential toxic substances. Human immortalized liver
cell lines could provide a solution to this problem. HepG2 and
Fa2N-4 cells were the first alternatives but these cells have lost
many liver-specific functions. In particular, expression levels of
many cytochromes P450 and several hepatic sinusoidal transport-
ers, including the uptake transporters were low or undetectable in
these human cell lines [6], [7], [8]. All of these drawbacks limit the
application of HepG2 and Fa2N-4 cells as an in vitro liver model
for transport, metabolism and hepatotoxicity studies. HepaRG cell
lines may be a potential tool for prediction of hepatotoxicity in
preclinical drug development [9], [7]. HepaRG cells have been
derived from a hepatocellular carcinoma cell line and can be
differentiated from bi-potent progenitor cells to two distinct
hepatic cell types, hepatocyte-like and biliary epithelial-like cells
under a certain culture condition [10], [11], [12], [13]. Presently,
only the HepaRG cells maintain several key hepatic functions,
including metabolic enzymes, drug transporters and nuclear
receptors at levels comparable with those found in primary human
hepatocytes [9], [14], [7].
The aim of our investigations was to determine, whether
HepaRG cells could replace human hepatocytes in toxicity studies
and the preclinical screening of drug candidates. The present
study mainly focussed on uptake processes; because we supposed
that hepatotoxicity in humans may be associated with drug-
mediated inhibition of uptake transporters [15], [16]. Many
studies have demonstrated that uptake transporters are essential in
the hepatic uptake of drugs from sinusoidal blood into the liver;
therefore they play a crucial role in the drug elimination rate [17],
[18]. Here we compared the inhibitory effect of drugs proved to be
cholestatic during clinical use [19], [20], [21] and bromosul-
fophthalein (BSP) on the uptake of taurocholate (TC) and estrone-
3-sulfate (E3S) in primary cultures of human, rat hepatocytes and
HepaRG cells. TC is a typical substrate of sodium taurocholate
cotrasporting polypeptide (NTCP/Ntcp) and some members of
organic anion transporting polypeptide super family (OATPs/
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Figure 1. TC and E3S uptake in primary human and rat hepatocyte cultures and HepaRG cell cultures as a function of culture time.
Cells were maintained in conventional monolayer culture. (A) Uptake of 3H-TC or (B) 3H-E3S (1mM) was measured for 30 sec (hepatocytes) or 300/
120 sec, TC/E3S, respectively (HepaRG cells) at 4, 24 and 96 h after seeding. The intracellular amount of TC or E3S was determined from the lysates of
the cells as described in Methods. Values are expressed as mean6SD, assays were run using four wells as one set. All experiments were carried out
with hepatocytes from three independent preparations.
doi:10.1371/journal.pone.0059432.g001
Figure 2. Phase-contrast image of HepaRG cells 4 h, 24 h and 96 h after seeding. H, hepatocyte-like cells; E, biliary epithelial-like cells.
doi:10.1371/journal.pone.0059432.g002
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Oatps) are involved in the hepatic uptake of E3S in human
(OATP1B1, OATP1B3 and OATP2B1) and rat (Oatp1a1,
Oatp1a4 and Oatp1b2) hepatocytes [22].
Methods
Materials
3H-taurocholate (10 Ci/mmol) and 3H-estrone-3-sulfate
(50 Ci/mmol) were obtained from American Radiolabeled
Chemicals Inc (St Louis, MO). Bromosulfophthalein, cyclosporin
A, estrone-3-sulfate, taurocholate, troglitazone, type IV collage-
nase, all cell culture media and reagents were purchased from
Sigma-Aldrich (Budapest, Hungary). Bosentan was from Sequoia
Research Products Ltd. (Pangbourne, UK). All other chemicals
and reagents were of analytical grade and were readily available
from commercial sources. Stock solutions of test compounds were
prepared in dimethyl sulfoxide (DMSO). 24-well plates were
obtained from Greiner Bio-One (Mosonmagyarovar, Hungary) or
Biopredic International (Rennes, France). Sterile collagen from rat
tail was prepared in-house according to established procedures.
Conventional primary hepatocyte cultures
The isolation and conventional primary culture of rat hepato-
cytes were performed as described previously [23]. Hepatocytes
from adult male Wistar rats (Charles River, Budapest) weighing
200 to 250 g were isolated by a previously described three-step
collagenase perfusion method [23], [24]. The protocol was
approved by the Institutional Animal Care and Use Committee
(Research Centre of Natural Sciences, HAS, Budapest) and the
Government Office for Pest County Food Chain Safety and
Animal Health Directorate, Budapest, Hungary (Permit Number:
22.1/2728/3/2011). All surgery was performed under diethyl
ether anesthesia, and all efforts were made to minimize suffering.
Human hepatocytes were prepared by perfusion of histologi-
cally normal liver fragments using a collagenase solution [23].
Human liver samples were obtained from adult donors undergoing
hepatic resection at Uzsoki Hospital (Budapest, Hungary). All of
the patients were operated with adenocarcinoma metastasis
hepatis, and their age was 52–71, all of whom provided a written
informed consent to participate in the study, which was approved
by Scientific and Research Ethics Committee of the Medical
Research Council (ETT-TUKEB ad.132/PI/2009-ad.8-47/2009-
1018EKU), in adherence to the declaration of Helsinki.
Cell viability (.90%) was routinely checked by the trypan blue
exclusion test. After preparation, freshly isolated cells were
suspended in Williams’ Medium E and plated at a cell density of
0.366106 cells per well in 24-well plates previously coated with rat
tail collagen. The cells were initially grown in Williams’ Medium E
containing 5% of fetal calf serum (FCS), 100 nM insulin, 0.05 mM
glucagon, 0.1 mg/ml gentamicin, 30 nM Na2SeO3, and 0.1 mM
dexamethasone. The medium was discarded 24 h after seeding
and hepatocytes were thereafter maintained in a serum-free
medium supplemented with glucagon, insulin, gentamicin, dexa-
methasone, Na2SeO3 and renewed daily. Cells were maintained at
37uC in a humidified atmosphere of 95% air-5% CO2.
Differentiated HepaRG cell cultures
The differentiated HepaRG (HPR116) cells were obtained from
Biopredic International (Rennes, France). According to the
supplier’s review these cryopreserved cells are terminally differen-
Figure 3. Comparison of the inhibition of TC uptake by
bosentan in human and rat hepatocyte cultures and HepaRG
cell cultures. (A) HepaRG cells were treated with 1 mM of 3H-TC for
300 sec at 4, 24 and 96 h after seeding in the presence of bosentan (10–
200 mM), or the vehicle, respectively. (B) Human and (C) rat hepatocytes
were treated with 1 mM of 3H-TC for 30 sec at 4, 24 and 72 h (rat) or 4,
120 h (human) after seeding in the presence of bosentan (10–100 mM),
or the vehicle, respectively. Values are expressed as mean6SD, assays
were run using four wells as one set. All experiments were carried out
with hepatocytes from three independent preparations.
doi:10.1371/journal.pone.0059432.g003
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tiated and exhibit many characteristics of primary human
hepatocytes including morphology, expression of key metabolic
enzymes, nuclear receptors, and drug transporters. The fully
differentiated HepaRG cultures seeded at high density contain
about 50% of hepatocyte-like cells shortly after plating and later
during culturing [10], [13]. HepaRG cells stored in liquid nitrogen
were thawed according to the instructions of the supplier and
resuspended in Basal medium for Thaw, Seed, and General
Purpose HepaRG medium (Biopredic International). After check-
ing viability the cells were seeded in collagen-coated 24-well plates
(Biopredic International) at a cell density of 0.486106 cells/well.
24 h after plating the medium was changed to Basal medium for
Maintenance (Biopredic International). The same procedure as
that for hepatocytes was then followed.
In vitro uptake experiments
For uptake experiments, HepaRG cells or/and hepatocytes
were used at 4, 24 and 96 h after plating, respectively. The uptake
assays were performed as described previously [25]. Briefly, the
wells were washed once with 0.4 ml of Hanks’ Balanced Salt
Solution (HBSS). The uptake experiment was started by the
addition of 0.4 ml of a HBSS solution containing the substrates
(1 mM 3H-TC or 3H-E3S) and lasted for 30 sec (hepatocytes) or
300/120 sec with TC/E3S, respectively (HepaRG cells) at 37uC.
The uptake was terminated by the removal of the substrate-
containing buffer, and the wells were washed three times with ice-
cold HBSS. Then the cells were lysed with 0.5 ml of 0.5% Triton
X-100 solution. The intracellular radioactivity was determined by
liquid scintillation counting. Protein content was determined by
the method of Lowry et al. [26]. Assays were run using four wells
in one set. All experiments were carried out with hepatocytes from
three independent cell preparations.
Drug interaction experiments
For drug interaction experiments, HepaRG cells were used at 4,
24 and 96 h, rat hepatocytes at 4, 24, 72 h and human
hepatocytes 4, 24 and 120 h after plating, respectively. We
investigated the inhibitory effect of drugs on the TC and E3S
uptake as a function of drug concentration using the three cell
types. The cells were incubated with 1 mM of 3H-TC or 3H-E3S in
the presence of the inhibitors, bosentan (10–200 mM), bromosul-
fophthalein (BSP) (1–500 mM), cyclosporin A (CsA) (0.5–100 mM),
troglitazone (5–100 mM), or the vehicle (DMSO, 0.1%), respec-
tively. The uptake lasted for 30 sec (hepatocytes) or 300/120 sec,
TC/E3S, respectively (HepaRG cells) at 37#C, and was
terminated by the removal of the substrate and the modulator-
containing medium. Then the cells were washed three times with
ice-cold HBSS and lysed with 0.5 ml of 0.5% Triton X-100
solution. The intracellular concentrations of the substrates were
determined by liquid scintillation counting. Assays were run using
four wells as one set. All experiments were carried out with
hepatocytes from three independent cell preparations.
Statistics
The results are expressed as mean6SD for all experiments.
Triplicate experiments of three independent hepatocyte isolations
were run, and four wells were used for each set of conditions. IC50
values were calculated using OriginPro 8.5 statistical software.
Results and Discussion
Effect of culture time on TC and E3S uptake
The effect of culture time on the uptake of TC and E3S was
studied in conventional monolayer cultures of human and rat
hepatocytes and HepaRG cells. The results are presented in
Figure 1A and 1B. The uptake experiments lasted for 30 sec in
case of primary hepatocytes, as we have already shown that the
TC and E3S uptake is very rapid, especially at short after seeding
[15]. In pilot studies, the uptake of TC and E3S was significantly
slower in HepaRG cells compared to that in the primary
hepatocytes, and was linear over a 5-min time period (data not
shown). These findings are in accord with a previous study [7]
demonstrating that expression of sinusoidal transporters such as
NTCP and OATPs but OATP2B1 is significantly lower in
HepaRG cells than in human hepatocytes. Therefore the
incubation time of the uptake experiments was set at 5 min for
TC and 2 min for E3S, respectively in case of HepaRG cell
cultures.
Similarly to our previous results [15] the uptake of TC
(Figure 1A) by rat hepatocytes measured at 4 h after seeding
decreased to 44% during 24 h (from 47.767.3 pmol/mg/min to
20.964.7 pmol/mg/min), and drastically dropped (to
1.260.7 pmol/mg/min) in the course of longer culturing time
(96 h). This observation is in accord with the findings of Rippin et
al. [27], who showed that in conventional monolayer culture of rat
hepatocytes the mRNA and protein levels of Ntcp and Oatp1a1
decreased to a few percent of the initial level by 72 h. On the
contrary, TC uptake activities remained relatively high in human
hepatocytes in the first 24 h after seeding (11.964.2 pmol/mg/
min and 10.461.8 pmol/mg/min), and slightly diminished
(6.662.1 pmol/mg/min) over time in culture. Our results are
confirmed by the work of Jigorel et al. [28], who demonstrated
that the mRNA level of NTCP was better maintained in a 3-day-
old human culture than in their rat counterparts. In HepaRG cells
the TC uptake significantly decreased by 24 h in culture (from
1.660.2 pmol/mg/min to 0.760.1 pmol/mg/min) but returned
to almost the initial value by 96 h (1.360.2 pmol/mg/min). This
Table 1. Inhibitory potential of drugs towards TC uptake.
Compound IC50 values (mM)
HepaRG cells Human hepatocytes Rat hepatocytes
4 h 24 h 96 h 4 h 24 h 120 h 4 h 24 h 72 h
Bosentan 50.9 .200 137.5 28.4 nta 44.8 8.9 9.7 48.4
Cyclosporin A 1.2 .50 4.7 2.4 5.0 .10 3.9 11.8 .100
Troglitazone 8.4 29.5 10.3 nt nt nt nt nt nt
ant = not tested.
Data are presented as mean of three independent cell preparations.
doi:10.1371/journal.pone.0059432.t001
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could be related to the fact that within a day following thaw and
seeding transporter activities decrease while the cells reconstitute
the monolayer, then the activities return similarly to CYP activities
[10]. The appearance of two, morphologically different cell types
in a 96 h HepaRG cell culture is demonstrated in Figure 2. A 7.2-
fold lower TC uptake was measured at short after seeding in
HepaRG cells compared to that observed in human hepatocytes,
in agreement with the findings of Le Vee et al [7].
E3S uptake (Figure 1B) significantly decreased in rat hepato-
cytes during culturing (from 154.164.0 pmol/mg/min to
32.6615.6 pmol/mg/min by 96 h); however, the decrease was
not as substantial as in the case of TC. Our data support that
Oatps are better maintained than the Ntcp in rat hepatocytes
during culturing. Human hepatocytes showed a smaller decrease
of E3S uptake compared with rat hepatocytes (from
21.968.0 pmol/mg/min to 10.865.5 pmol/mg/min, from 24 h
to 96 h). These observations are consistent with the report of
Jigorel et al. [28], who described better maintained Oatps/OATPs
activities in both rat and human hepatocyte cultures. In HepaRG
cells, E3S uptake did not change significantly, with time in culture.
Approximately a 3-fold lower E3S uptake was measured in a 96-
hour-old HepaRG and human hepatocyte culture than in rat
hepatocytes.
Effect of Bosentan and CsA on TC uptake
The inhibition of normal bile acid transport is one of the
possible mechanisms causing hepatotoxicity [20]. In this work, we
focussed primarily on compounds that were shown to modulate
bile salt homeostasis mostly by BSEP inhibition [29]. Kostrubsky
et al. [30] reported that bosentan and CsA inhibit bile acid biliary
excretion in sandwich-cultured human hepatocytes. Although it
has been shown that some of these xenobiotics may alter bile acid
homeostasis by inhibiting both hepatic uptake and canalicular
efflux of them [15], [31], the effect of these drugs using HepaRG
cell line as a model has not been investigated yet. TC, an
endogenous compound, is commonly used as a model substrate for
bile acid transport studies. It is well published that the hepatic
uptake of TC is predominantly mediated by NTCP/Ntcp [32],
[33], which is expressed exclusively in the liver. Human NTCP has
a higher affinity towards TC than rat Ntcp (Km of 6 and 25 mM,
respectively) [22]. It is worth mentioning that most of the drugs
that have been proved to inhibit bile salt uptake are not
transported by NTCP/Ntcp.
Figure 3A, 3B and 3C show the concentration-dependent
inhibition of TC uptake by bosentan in the three cell types.
Bosentan, which is a substrate for OATP1B1 and OATP1B3 and
not transported by NTCP [18], decreased the TC uptake with an
approximately 3-fold lower IC50 in freshly seeded rat than human
hepatocytes (IC50 of 8.9 and 28.4 mM respectively) (Table 1). Our
results are in accord with the findings of Leslie et al. [31], who
described an IC50 of 5.4 mM and 30 mM for bosentan in primary
rat and human hepatocyte suspensions, respectively. However, this
difference between the IC50 values obtained with the two cell types
vanished in time, suggesting that the expression of hepatic uptake
transporters is better preserved in primary human than in rat
hepatocytes. In HepaRG cells at 4 h after seeding bosentan
inhibited TC uptake with an approximately 2-fold higher IC50
than in human hepatocytes (Table 1). In a 24 h HepaRG culture
the decrease of TC uptake was not more than 40% of the control
even at 200 mM bosentan concentration. By 96 h, the inhibition
Figure 4. Comparison of the inhibition of TC uptake by
cyclosporin A in human and rat hepatocyte cultures and
HepaRG cell cultures. (A) HepaRG cells were treated with 1 mM of 3H-
TC for 300 sec at 4, 24 and 96 h after seeding in the presence of
cyclosporin A (0.5–50 mM), or the vehicle, respectively. (B) Human and
(C) rat hepatocytes were treated with 1 mM of 3H-TC for 30 sec at 4, 24
and 120 h (human) or 4, 24 and 72 h (rat) after seeding in the presence
of cyclosporin A (0.5–10 mM or 0.5–100 mM), or the vehicle, respectively.
Values are expressed as mean6SD, assays were run using four wells as
one set. All experiments were carried out with hepatocytes from three
independent preparations.
doi:10.1371/journal.pone.0059432.g004
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potential of bosentan increased, but did not reach the effectiveness
observed at 4 h after seeding (Table 1). These findings are in close
relation with the results of the uptake studies. A declining TC
uptake observed in all cell types was probably due to the reduced
expression of NTCP/Ntcp, which resulted in a loss of the
inhibition capacity of drugs. In contrast to the primary hepatocytes
HepaRG cells regained part of their TC uptake capacity during
culturing, which led to the increase of drug effect. It is worth
mentioning that in cholangiocyte-like cells the apical sodium-
dependent bile salt transporter (ASBT/SLC10A2), which is
involved in the enterohepatic circulation of bile salts, might have
a different affinity towards the drugs studied, and may contribute
to the inhibition of TC uptake in the HepaRG cell cultures at 96 h
[34], [10].
Figure 4A, 4B and 4C show the decrease in TC uptake as a
function of CsA concentration in human and rat hepatocytes and
HepaRG cells. The extent of inhibition was similar in HepaRG
cells and human hepatocytes, and it was less pronounced in rat
cells at 4 h after seeding. This observation is consistent with
previous reports showing that CsA inhibited human NTCP more
efficiently than rat Ntcp [35], [36]. The inhibitory effect of CsA
was similar in 24 h human hepatocytes and 96 h HepaRG cells
(IC50 of 5.0 and 4.7 mM respectively) (Table 1). The inhibitory
potential of CsA, just like that of bosentan, dramatically decreased
in a 3-day-old rat hepatocyte culture. CsA proved to be a more
potent inhibitor than bosentan in all cell types. CsA is able to
inhibit both sodium-dependent (NTCP) and sodium-independent
(OATP1B1, OATP1B3) TC uptake into human hepatocytes,
which may contribute to its higher interaction potential observed
[37], [18].
Effect of Troglitazone on TC uptake
Troglitazone was removed from US markets in 2000 because its
use was associated with liver failure [38]. Funk et al. [21]
demonstrated that troglitazone inhibits Bsep-mediated TC biliary
excretion in a concentration-dependent manner in rat hepato-
cytes. We investigated whether this drug decreases the TC uptake
also in HepaRG cells. The concentration dependent effect of
troglitazone on TC uptake by HepaRG cells is shown in Figure 5.
Troglitazone inhibited the uptake of TC with almost the same
IC50 (8.4 and 10.3 mM) at 4 and 96 h (Table 1). IC50 measured at
24 h was about 3-fold higher than that at 4 h and 96 h supporting
the regained NTCP expression by 96 h. Marion et al. [12]
examined the effect of troglitazone on the transport of TC in
human and rat hepatocyte suspension and demonstrated that
troglitazone was a more potent inhibitor for human NTCP (IC50
of 0.33 mM) than for rat Ntcp (IC50 of 2.3 mM). The difference
between NTCP versus Ntcp inhibition could be one reason for
species differences regarding drug-induced hepatotoxicity.
Preliminary viability studies (MTT assay) confirmed that the
cholestatic drugs applied in the uptake experiments were not
cytotoxic for either cell type even at the highest concentration used
(data not shown).
Effect of BSP on E3S uptake
Furthermore, we also examined the interaction potential of BSP
concerning the E3S uptake in the cell cultures (Figure 6A and 6B).
As shown in Figure 6B, BSP inhibited the E3S uptake with a 2.8-
fold lower IC50 in human than in rat hepatocytes at 24 h after
seeding. In HepaRG cells BSP decreased the uptake of E3S with
an IC50 of 5.0 mM at 4 h after seeding (Figure 6A). Although the
uptake rate of E3S was constant during culturing, the inhibitory
effect of BSP decreased by 24 h and did not change thereafter.
This inhibitory pattern of BSP seems to be different from that
found in the case of drugs influencing TC uptake, where the IC50
values were always much lower at 96 than at 24 hours after
seeding. Further studies are needed to estimate the expression level
of different OATPs involved in the uptake of E3S as a function of
culture time and cell cycle in HepaRG cells in order to elucidate
the inhibition pattern obtained for BSP. In a recent paper Kotani
Figure 5. Inhibition of TC uptake by troglitazone in HepaRG cells. HepaRG cells were treated with 1 mM of 3H-TC for 300 sec at 4, 24 and
96 h after seeding in the presence of troglitazone (5–100 mM), or the vehicle. Values are expressed as mean6SD, assays were run using four wells as
one set.
doi:10.1371/journal.pone.0059432.g005
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et al. [39] studied the inhibition potencies of 12 OATP1B1
inhibitors both in HepaRG cells and in OATP1B1-expressing
HEK293 cells and demonstrated the usefulness of HepaRG cells
for the characterization of OATP1B1-mediated drug-drug inter-
actions.
In conclusion, we demonstrated the applicability of HepaRG
cell line as a potential alternative to primary human hepatocytes in
an uptake model and suggest that HepaRG cells can help predict
drug related hepatotoxicity in humans. So far, this is the first
report in which drug interaction with taurocholate and estrone-3-
sulfate uptake transport was presented in an immortalized cell line.
We demonstrated that concerning the inhibition of TC uptake
process, HepaRG cells are closer to human hepatocytes than rat
hepatocytes. It should be kept in mind that the expression levels of
sinusoidal drug transporters are lower in HepaRG cells than in
primary hepatocyte cultures, so longer incubation times are
Figure 6. Comparison of the inhibition of E3S uptake by bromosulfophthalein in human and rat hepatocytes and HepaRG cells. (A)
HepaRG cells were treated with 1 mM of 3H-E3S for 120 sec at 4, 24 and 96 h after seeding in the presence of bromosulfophthalein (1–500 mM), or the
vehicle. (B) Human and rat hepatocytes were treated with 1 mM of 3H-E3S for 30 sec at 24 h after seeding in the presence of bromosulfophthalein (1–
500 mM), or the vehicle. Values are expressed as mean6SD, assays were run using four wells as one set. All experiments were carried out with
hepatocytes from three independent preparations.
doi:10.1371/journal.pone.0059432.g006
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needed [7]. And it is noteworthy that culture time is a critical
parameter for drug interaction, which corresponds with our
findings in our previous report [15]. A shorter culture time
provides more reliable results of drug interaction potential with
uptake transporters. Taking all together, our results suggest that
HepaRG cell line may be a suitable model to study not only
metabolic processes but uptake transport as well.
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